Guest: Rasheda Persinger MSN, AGNP-C, AOCNP Guest: Terran Sims, MSN, ACNP-C, CNN, COCN-C In this activity, learn about the most recent recommendations for biomarker/molecular testing and personalized treatment plans for patients with non-sma

Guest: Terran Sims, MSN, ACNP-C, CNN, COCN-C Guest: Laura M. Spring, MD Watch this educational activity to learn about the integration of novel agents into the treatment algorithm for patients with triple-negative breast cancer (TNBC) and cu

Guest: Sarah Tinsley-Vance, PhD, MSN, APRN-BC, AOCN Guest: Terran Sims, MSN, ACNP-C, CNN, COCN-C In this eCourse tailored to advanced practice providers, get up to date on optimal care of patients with myelodysplastic syndromes (MDS), includ

Host: Charu Aggarwal, MD, MPH Host: Patrick Forde, M.B.B.Ch. The treatment options for non-small cell lung cancer (NSCLC) are constantly evolving, making it challenging for healthcare professionals to stay updated with the latest scientific

Host: Charu Aggarwal, MD, MPH Host: Patrick Forde, M.B.B.Ch. The treatment options for non-small cell lung cancer (NSCLC) are constantly evolving, making it challenging for healthcare professionals to stay updated with the latest scientific

Guest: Mary Weinstein Dunn Watch this educational activity to learn about the latest guideline-recommended first-line and later-line treatments for advanced renal cell carcinoma (RCC), as well as strategies to manage adverse (AEs) events of nove

Host: Ellie Kelepouris, MD, FACP, FAHA Guest: Stephen J. Greene, MD, FACC, FHFSA Patients with heart failure and chronic kidney disease (CKD) are challenging to manage. The best approach is a multidisciplinary one, which will help to optimiz

Host: Durga Borkar, MD, MMCi Host: Christina Y. Weng, MD, MBA The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME),

Host: Sabin Dang, MD Host: Jayanth Sridhar, MD The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do the

Host: Christina Y. Weng, MD, MBA Host: Durga Borkar, MD, MMCi The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME),